on Beta Bionics
Xeris Biopharma Announces Collaboration With Beta Bionics for Bi-Hormonal Pump Development
CONCORD, MA – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. This partnership focuses on the development and commercialization of a new glucagon formulation using Xeris' XeriSol™ technology, aimed for use in Beta Bionics’ bi-hormonal pump systems designed for diabetes management.
Paul R. Edick, Chairman and CEO of Xeris, expressed enthusiasm about partnering with Beta Bionics, emphasizing the rapid support Xeris plans to offer in this significant venture. Beta Bionics' CEO, Sean Saint, highlighted the operational analogy of insulin and glucagon to a car’s gas pedal and brakes, respectively, underscoring the advantages of their bi-hormonal system over traditional insulin-only treatments.
The licensing agreement stipulates that Xeris could receive development payments and royalties from future sales of their specially formulated glucagon for these innovative pump systems.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Beta Bionics news